Connect Biopharma Holdings Ltd. (CNTB)
0.59
-0.04
(-6.08%)
USD |
NASDAQ |
Nov 20, 16:00
0.5897
0.00 (0.00%)
After-Hours: 20:00
Connect Biopharma Holdings Research and Development Expense (TTM) : 55.37M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 55.37M |
| June 30, 2026 | 53.70M |
| Date | Value |
|---|---|
| March 31, 2026 | 46.20M |
| December 31, 2025 | 37.80M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Anavex Life Sciences Corp. | 11.44M |
| Vaxcyte, Inc. | 1.093B |
| Foghorn Therapeutics, Inc. | 76.22M |
| Caribou Biosciences, Inc. | 84.72M |
| Oncolytics Biotech, Inc. | 13.18M |